Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Rating of “Hold” from Analysts

Elanco Animal Health Incorporated (NYSE:ELAN) has been given an average rating of “Hold” by the seven brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $17.14.

A number of research firms have commented on ELAN. Barclays lifted their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. Morgan Stanley lowered shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $17.00 to $15.00 in a report on Thursday, September 19th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $20.00 price target on shares of Elanco Animal Health in a report on Thursday, September 19th.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $13.44 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The firm has a market cap of $6.64 billion, a P/E ratio of 33.60, a P/E/G ratio of 1.46 and a beta of 1.41. The firm has a 50 day simple moving average of $13.74 and a 200 day simple moving average of $14.76. Elanco Animal Health has a fifty-two week low of $11.40 and a fifty-two week high of $18.80.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter last year, the business posted $0.18 earnings per share. Elanco Animal Health’s revenue for the quarter was down 3.6% compared to the same quarter last year. Sell-side analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Davidson Kempner Capital Management LP bought a new stake in shares of Elanco Animal Health in the 2nd quarter valued at about $839,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Elanco Animal Health by 4.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,139,018 shares of the company’s stock valued at $360,425,000 after purchasing an additional 852,281 shares during the period. Canada Pension Plan Investment Board bought a new stake in shares of Elanco Animal Health in the 2nd quarter valued at about $55,599,000. XTX Topco Ltd bought a new stake in shares of Elanco Animal Health in the 2nd quarter valued at about $935,000. Finally, SG Capital Management LLC bought a new stake in shares of Elanco Animal Health in the 1st quarter valued at about $4,211,000. 97.48% of the stock is owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.